Idera Pharmaceuticals Announces FDA Authorization to Proceed with a Phase 2 Clinical Trial of IMO-3100
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the receipt of verbal notification from the Food and Drug Administration that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011. IMO-3100 is a dual antagonist of Toll-like receptor (TLR) 7 and TLR9 and is in clinical development as a potential therapy for autoimmune and inflammatory diseases.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.